MAXCYTE, INC.
About MAXCYTE, INC.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $21.0M
- Net income
- -$44.6M
- Total assets
- $202.5M
- Market cap
- $122.1M
- Gross margin
- 81.2%
- Operating margin
- -157.1%
- Net margin
- -135.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $33.0M
- Cost of revenue
- $6.2M
- Gross profit
- $26.8M
- Operating expenses
- $78.7M
- Operating income
- -$51.9M
- Net income
- -$44.6M
- EPS (basic)
- $-0.42
- EPS (diluted)
- $-0.42
Balance sheet
- Total assets
- $202.5M
- Current assets
- $118.4M
- Total liabilities
- $31.0M
- Current liabilities
- $14.3M
- Shareholders’ equity
- $171.5M
Cash flow
- Operating cash flow
- -$34.4M
- Investing cash flow
- $25.9M
- Financing cash flow
- $656.0K
- Net cash flow
- -$7.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $122.1M
- EPS (diluted)
- $-0.42
- Shares outstanding
- 106.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 5, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $44.6M in FY2025.
- Revenue declined 3% from FY2021 to FY2025.
- Gross margin of 81.2%, net margin -135.1%.
- Trading 58% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MAXCYTE, INC..
Write a review
News about MAXCYTE, INC.
News & sentiment via Polygon.io
